Baricitinib Medicine 04 December 2025 Extended indication Baricitinib is indicated for the treatment of severe alopecia areata in adult and adolescent patients 12 years of age and older (see section 5.1). Therapeutic value No estimate possible yet Total cost € 3,580,200.00 Registration phase Registered Product Active substance Baricitinib Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Skin diseases Extended indication Baricitinib is indicated for the treatment of severe alopecia areata in adult and adolescent patients 12 years of age and older (see section 5.1). Current proprietary name Already available biosimilars / generics Proprietary name Olumiant Manufacturer Eli Lilly Portfolio holder Mechanism of action JAK tyrosine kinase inhibitor Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date August 2025 Expected Registration March 2026 Orphan drug No Registration phase Registered Reimbursement Medicine sluice Additional remarks Indicatieuitbreiding van baricitinib voor de behandeling van ernstige alopecia areata bij adolescente patiënten van 12 jaar en ouder (zie rubriek 5.1). Is EC geregistreerd per maart 2026. Therapeutic value Current treatment options Corticosteroïden, lokale immuuntherapie, lichttherapie, ciclosporine, Minoxidil, prikkeltherapie, dithranol. Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT05723198 (I4V-MC-JAIO) Additional remarks Expected patient volume per year Patient volume < 459 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References GVS-advies ritlecitinib (Litfulo®) voor de behandeling van ernstige alopecia areata. Zorginstituut Nederland. 2024. Additional remarks Er wordt aangenomen dat er 459 prevalente patiënten en 25 incidentie patiënten zijn tussen de 12 en 17 jaar oud met alopecea areata en die in aanmerking komen voor een dergelijke behandeling. Expected cost per patient per year Cost € 7,800.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References G-standaard Additional remarks De prijs voor een verpakking van 28 tabletten Olumiant 4 mg bedraagt op basis van de januari 2026 AIP 640 euro. Kosten op basis van IHSI-inschatting, afgeleid van de mediane kosten van het geneesmiddel in Nederland. Potential total cost per year Total cost € 3,580,200.00 Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks